医学新知2023，Vol.33Issue(6)：438-449,12.DOI:10.12173/j.issn.1004-5511.202212027
R-GemOx方案治疗复发难治性B细胞淋巴瘤有效性和安全性的单臂Meta分析
Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma:a single-arm Meta analysis
摘要
Abstract
Objective Systematic evaluation of the efficacy and safety of the Rituximab plus gemcitabine and oxaliplatin(R-GemOx)regimen for the treatment of relapsed refractory B-cell lymphoma.Methods The PubMed,Embase,CNKI,CBM,VIP and Wan-Fang databases were systematically searched for experimental and observational studies on the R-GemOx regimen for relapsed refractory B-cell lymphoma.The search time frame is from the establishment of each database to September 13,2022.After extracting the literature and evaluating the quality of the literature in parallel,Meta-analysis was performed using R(4.2.1)software.Results A total of 526 cases of relapsed refractory B-cell lymphoma were included in 13 studies.Meta-analysis showed that the complete response rate(CRR)was 37.48%[95%CI(30.25%,46.45%)];partial response rate(PRR)was 28.62%[95%CI(21.06%,38.90%)];stable disease rate(SDR)was 12.03%[95%CI(7.03%,17.93%)];progressive disease rate(PDR)was 21.20%[95%CI(15.73%,27.22%)];over response rate(ORR)was 62.19%[95%CI(52.25%,74.02%)];clinical benefit rate(CBR)was 79.40%[95%CI(72.49%,85.62%)].Safety was dominated by hematological system toxicity,digestive system toxicity and nervous system toxicity.Conclusion The R-GemOx regimen for relapsed refractory B-cell lymphoma is an effective treatment option with tolerable drug toxicity.关键词
R-GemOx方案/复发难治性B细胞淋巴瘤/单臂Meta分析/有效性/安全性Key words
R-GemOx/Relapsed refractory B-cell lymphoma/Single-arm Meta analysis/Efficacy/Safety引用本文复制引用
黄国鑫,曹启龙,田建洲,艾金伟,屈高静,裴斌..R-GemOx方案治疗复发难治性B细胞淋巴瘤有效性和安全性的单臂Meta分析[J].医学新知,2023,33(6):438-449,12.基金项目
湖北省"323"攻坚行动襄阳市第一人民医院重点专项科研基金(XYY2022-323) （XYY2022-323）
襄阳市第一人民医院科技创新项目(XYY2023SD06) （XYY2023SD06）
